Kamada (KMDA) Share-based Compensation (2012 - 2026)
Kamada's (KMDA) quarterly Share-based Compensation came in at $800000.0 in Q1 2026, up 357.14% YoY from $175000.0 in Q1 2025, and up 127.92% on a QoQ basis from $351000.0 in Q4 2025.
Kamada (KMDA) Share-based Compensation (2012 - 2026) Analysis & Trends
Kamada (KMDA) has 15 years of Share-based Compensation data on file, last reported at $800000.0 in Q1 2026.
- Quarterly Share-based Compensation rose 357.14% year-over-year to $800000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 75.87% YoY) and the FY2025 annual result came in at $845000.0, down 74.42% from the prior year.
- Share-based Compensation climbed to $800000.0 in Q1 2026, from $351000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.7 million in Q4 2023 to a low of $366.0 in Q3 2022.
- A 5-year average of $362693.0 and a median of $214000.0 in 2023 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 85145.9% in 2023, down 99.78% in 2023.
- Tracing KMDA's Share-based Compensation over 5 years: stood at $25000.0 in 2022, then jumped by 10564.0% to $2.7 million in 2023, then tumbled by 94.71% to $141000.0 in 2024, then surged by 148.94% to $351000.0 in 2025, then jumped by 127.92% to $800000.0 in 2026.
- The last three Share-based Compensation figures came in at $800000.0 (Q1 2026), $351000.0 (Q4 2025), and $117000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Kamada | 465.49 Mn | 436.02 Mn | 22.47 Mn | 720,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 720,000.00 |
| Jun 30, 2026 | 720,000.00 |
| Mar 31, 2026 | 800,000.00 |
| Mar 31, 2026 | 800,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Sep 30, 2025 | 117,000.00 |
| Sep 30, 2025 | 117,000.00 |
| Jun 30, 2025 | 95,000.00 |
| Jun 30, 2025 | 95,000.00 |
| Mar 31, 2025 | 175,000.00 |
| Mar 31, 2025 | 175,000.00 |
| Dec 31, 2024 | 141,000.00 |
| Dec 31, 2024 | 141,000.00 |
| Sep 30, 2024 | 224,000.00 |
| Sep 30, 2024 | 224,000.00 |
| Jun 30, 2024 | 235,000.00 |
| Jun 30, 2024 | 235,000.00 |
| Mar 31, 2024 | 241,000.00 |
| Mar 31, 2024 | 241,000.00 |